Peptide Library

Human evidence quality

Elamipretide (SS-31): what the human research shows

Certainty varies by clinical outcome. Each claim below is assessed on its own; open one to see the studies and the reasoning.
FDA-approved · Last assessment published November 8, 2026 · Methodology ev-1

Evidence overview

Research volume and reviewed human evidence are different numbers, kept apart.

Indexed publications

398

Research snapshot 2026.1.1

Human clinical publications

30

PubMed records classified as human research

Distinct human studies reviewed

51

of 54 identified

Randomized controlled studies

16

among reviewed studies

Studies with reported results

27

Registered, no results available

14

Unpublished is not negative

Study results assessed for risk of bias

100

Outcomes with a certainty assessment

3

Research volume for Elamipretide (SS-31) · Library profile

Claims evaluated

Claims are things to investigate, never established benefits. Evidence for one outcome doesn’t carry over to another.

Claims evaluated for Elamipretide (SS-31)
Claim being evaluatedEligible human studiesCertainty by outcome
Improves exercise capacity in primary mitochondrial myopathy4
Improves function in Barth syndrome2
Is safe for human administrationSafety15

Human studies

Each distinct study once, however many papers, abstracts or registrations describe it.

Elamipretide in pediatric Barth syndrome: from heart failure to school return.Case report · 1 participants · first reported 2026 · automated, not human-reviewed

Population: A 5-year-old (preschool-aged) boy with genetically confirmed Barth syndrome and advanced heart failure. At start he had severe left ventricular dysfunction and moderate-to-severe mitral regurgitation, depended on gastrostomy feeding and was listed for heart transplantation.

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Left ventricular ejection fraction (LVEF): Serious concern (Structured limitations appraisal); Mitral regurgitation severity: Serious concern (Structured limitations appraisal); Ross heart failure class: Serious concern (Structured limitations appraisal); Functional capacity / exercise tolerance: Serious concern (Structured limitations appraisal); Nutritional status: Serious concern (Structured limitations appraisal); Health-related quality of life: Serious concern (Structured limitations appraisal); Return to school: Serious concern (Structured limitations appraisal); Heart transplant listing status: Serious concern (Structured limitations appraisal); Adverse events / tolerability: Serious concern (Structured limitations appraisal)

Full study record (PLS-00097)
Expanded-Access Use of Elamipretide Improves Quality of Life in Patients With Rare Mitochondrial Disorders Characterized by Ophthalmic Symptoms: A Case Series.Case series · 2 participants · first reported 2024 · automated, not human-reviewed

Population: Two patients with different progressive mitochondrial disorders with ophthalmic features: chronic progressive external ophthalmoplegia (CPEO) plus, and neuropathy, ataxia and retinitis pigmentosa (NARP) syndrome.

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Symptoms and quality of life: Serious concern (Structured limitations appraisal); Tolerability: Serious concern (Structured limitations appraisal)

Full study record (PLS-00098)
Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report.Case report · 1 participants · first reported 2025 · automated, not human-reviewed

Population: A male infant diagnosed in utero with Barth syndrome. At birth he had a moderately dilated left ventricle with reduced ejection fraction and needed intubation and haemodynamic support.

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Left ventricular ejection fraction: Serious concern (Structured limitations appraisal); Oxygen weaning and hospital discharge: Serious concern (Structured limitations appraisal)

Full study record (PLS-00099)
Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.Randomized controlled trial · 218 participants · first reported 2017 · automated, not human-reviewed

Population: Adults with genetically confirmed primary mitochondrial myopathy in MMPOWER-3. 74% had mtDNA pathogenic variants or single large-scale mtDNA deletions. The rest had nDNA variants, mostly in mtDNA replisome genes such as POLG and TWNK. Analyzed post hoc by genotype subgroup.

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Six-minute walk test distance, overall trial population: Some concerns (Cochrane RoB 2); Six-minute walk test distance, prespecified nDNA and mtDNA subgroups: Some concerns (Cochrane RoB 2); Six-minute walk test change, mtDNA replisome post hoc cohort: High risk of bias (Cochrane RoB 2); Six-minute walk test change, replisome subjects with CPEO: High risk of bias (Cochrane RoB 2); Exposure-response: plasma elamipretide concentration vs 6MWT improvement, nDNA cohort: High risk of bias (Cochrane RoB 2)

Full study record (PLS-00100)
Cardiac pathology in a patient with a novel pathogenic variant c.703del (p.Ile235SerfsTer4) of the TAFAZZIN gene.Case report · 1 participants · first reported 2025 · automated, not human-reviewed

Population: A full-term male infant with Barth syndrome due to a novel pathogenic TAFAZZIN c.703del variant. He presented with postnatal cardiogenic shock that required VA-ECMO and was waitlisted for cardiac transplantation.

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Tolerability of elamipretide: Serious concern (Structured limitations appraisal); Cardiac transplantation and clinical course: Serious concern (Structured limitations appraisal); Explanted heart pathology: Serious concern (Structured limitations appraisal)

Full study record (PLS-00101)
Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report.Case report · 1 participants · first reported 2025 · automated, not human-reviewed

Population: A single neonate with prenatally identified Barth syndrome. The infant had severe left ventricular non-compaction cardiomyopathy and clinical heart failure, and was on the heart transplant list.

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Clinical heart failure status and heart transplant listing status: Serious concern (Structured limitations appraisal)

Full study record (PLS-00102)
Expanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration.Case report · 1 participants · first reported 2024 · automated, not human-reviewed

Population: A single progressively declining 17-year-old female patient with membrane protein-associated neurodegeneration (MPAN)

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Symptoms (dysarthria, dysphagia, gait): Serious concern (Structured limitations appraisal); 6-minute walk test: Serious concern (Structured limitations appraisal); 5 times sit-to-stand test: Serious concern (Structured limitations appraisal)

Full study record (PLS-00103)
ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation.Randomized controlled trial · 176 participants · first reported 2019 · automated, not human-reviewed

Population: Patients aged 55 years or older with at least one eye with dry age-related macular degeneration and noncentral geographic atrophy.

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Mean change from baseline in low-luminance best-corrected visual acuity (LL BCVA): Some concerns (Cochrane RoB 2); Change from baseline in square-root converted geographic atrophy area: Some concerns (Cochrane RoB 2); Progression of macular percentage of total ellipsoid zone attenuation/loss: Some concerns (Cochrane RoB 2); Progression of macular percentage of partial ellipsoid zone attenuation/degradation: Some concerns (Cochrane RoB 2); Proportion of patients with a gain of 10 or more letters in LL BCVA: Some concerns (Cochrane RoB 2); Incidence and severity of adverse events: Some concerns (Cochrane RoB 2)

Full study record (PLS-00104)
Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.Randomized controlled trial · 12 participants · first reported 2023 · automated, not human-reviewed

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Adverse events: Some concerns (Cochrane RoB 2); Change from baseline in best-corrected visual acuity (BCVA): Some concerns (Cochrane RoB 2); Central visual field mean deviation (Humphrey automated visual field central region): High risk of bias (Cochrane RoB 2)

Full study record (PLS-00105)
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.Single-arm trial · Not reported participants · first reported 2017 · automated, not human-reviewed

Population: Patients with Barth syndrome who had completed the 28-week randomized, double-blind, placebo-controlled phase of TAZPOWER and entered the 168-week open-label extension.

Assessed from the abstract only: essential methods may be missing.

Risk of bias: 6-minute walk test distance: Serious concern (Structured limitations appraisal); BTHS-SA Total Fatigue score: Serious concern (Structured limitations appraisal); Safety and tolerability: Serious concern (Structured limitations appraisal); 3D echocardiographic left ventricular volumes: Serious concern (Structured limitations appraisal); MLCL/CL ratio: Serious concern (Structured limitations appraisal)

Full study record (PLS-00106)
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.Randomized controlled trial · 218 participants · first reported 2023 · automated, not human-reviewed

Population: Participants with genetically confirmed primary mitochondrial myopathy, most with mtDNA alterations and the rest with nDNA defects. Mean age 45.6 years, 64% women, 94% White.

Assessed from the abstract only: essential methods may be missing.

Risk of bias: 6-minute walk test distance: Some concerns (Cochrane RoB 2); PMMSA total fatigue score: Some concerns (Cochrane RoB 2); Adverse events: High risk of bias (Cochrane RoB 2)

Full study record (PLS-00107)
Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases.Case series · Not reported participants · first reported 2022 · automated, not human-reviewed

Population: Pediatric patients aged under 12 years with rare mitochondrial (orphan) disorders treated with elamipretide under a compassionate use program; the specific diagnoses are not stated in the abstract.

Assessed from the abstract only: essential methods may be missing.

Full study record (PLS-00108)
Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.Randomized controlled trial · 12 participants · first reported 2023 · automated, not human-reviewed

Population: Patients with Barth syndrome enrolled in a randomized, double-blind, placebo-controlled crossover trial of elamipretide.

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Accuracy of clustering patients by functional status from wearable physiological data: High risk of bias (Cochrane RoB 2); Accuracy of clustering responders vs non-responders to elamipretide: High risk of bias (Cochrane RoB 2)

Full study record (PLS-00109)
Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.Retrospective cohort · Not reported participants · first reported 2022 · automated, not human-reviewed

Population: Patients with Barth syndrome: 8 elamipretide-treated patients from the TAZPOWER open-label extension and 19 untreated natural history controls, 12 of whom had serial echocardiographic assessments.

Assessed from the abstract only: essential methods may be missing.

Risk of bias: 6-minute walk test distance: No information (ROBINS-I); Muscle strength by handheld dynamometry: No information (ROBINS-I); 5 times sit-to-stand: No information (ROBINS-I); Multi-domain responder index: No information (ROBINS-I); Left ventricular stroke volume: No information (ROBINS-I)

Full study record (PLS-00110)
Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.Randomized controlled trial · 36 participants · first reported 2018 · automated, not human-reviewed

Population: Adults with genetically confirmed primary mitochondrial myopathy (PMM)

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Change in 6-minute walk test distance: High risk of bias (Cochrane RoB 2); Cardiopulmonary exercise testing parameters: Some concerns (Cochrane RoB 2); Participant-reported symptoms: Some concerns (Cochrane RoB 2); Serum and urinary biomarkers: Some concerns (Cochrane RoB 2); Safety and tolerability: Some concerns (Cochrane RoB 2)

Full study record (PLS-00111)
A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.Randomized controlled trial · 12 participants · first reported 2020 · automated, not human-reviewed

Population: Subjects with Barth syndrome (BTHS), a genetic condition caused by TAZ defects that produce abnormal mitochondrial cardiolipin. Age and sex are not stated in the abstract.

Assessed from the abstract only: essential methods may be missing.

Full study record (PLS-00112)
Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.Single-arm trial · 21 participants · first reported 2021 · automated, not human-reviewed

Population: Adults aged 55 years or older with intermediate age-related macular degeneration and high-risk drusen (preplanned HRD cohort)

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Adverse events and tolerability: Serious concern (Structured limitations appraisal); Normal-luminance best-corrected visual acuity (BCVA): Serious concern (Structured limitations appraisal); Low-luminance best-corrected visual acuity (LLVA): Serious concern (Structured limitations appraisal); Normal-luminance binocular reading acuity (NLRA): Serious concern (Structured limitations appraisal); Low-luminance binocular reading acuity (LLRA): Serious concern (Structured limitations appraisal); RPE-drusen complex volume by OCT: Serious concern (Structured limitations appraisal); Fundus autofluorescence: Serious concern (Structured limitations appraisal); Mesopic microperimetry: Serious concern (Structured limitations appraisal); Dark adaptation: Serious concern (Structured limitations appraisal)

Full study record (PLS-00113)
Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study.Single-arm trial · 19 participants · first reported 2021 · automated, not human-reviewed

Population: Adults aged 55 years or older with dry age-related macular degeneration and noncentral geographic atrophy

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Safety and tolerability (adverse events): Serious concern (Structured limitations appraisal); Normal-luminance best-corrected visual acuity (BCVA): Serious concern (Structured limitations appraisal); Low-luminance best-corrected visual acuity (LLBCVA): Serious concern (Structured limitations appraisal); Low-luminance binocular reading acuity (LLBRA): Serious concern (Structured limitations appraisal); Normal-luminance binocular reading acuity (NLBRA): Serious concern (Structured limitations appraisal); Geographic atrophy area: Serious concern (Structured limitations appraisal); Low-luminance questionnaire (LLQ) self-reported function: Serious concern (Structured limitations appraisal)

Full study record (PLS-00114)
Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial.Randomized controlled trial · 71 participants · first reported 2020 · automated, not human-reviewed

Population: Patients with stable heart failure with reduced ejection fraction (LVEF at or below 40%). Mean age 65 years, 24% female, mean EF 31%.

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Change in left ventricular end systolic volume (LVESV): Some concerns (Cochrane RoB 2); Change in left ventricular ejection fraction (LVEF): Some concerns (Cochrane RoB 2); Study drug-related adverse events: Some concerns (Cochrane RoB 2)

Full study record (PLS-00115)
A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.Randomized controlled trial · 30 participants · first reported 2020 · automated, not human-reviewed

Population: Adults with genetically confirmed primary mitochondrial myopathy

Assessed from the abstract only: essential methods may be missing.

Risk of bias: 6-minute walk test distance: Some concerns (Cochrane RoB 2); PMMSA Total Fatigue score: Some concerns (Cochrane RoB 2); PMMSA Total Fatigue During Activities score: Some concerns (Cochrane RoB 2); Neuro-QoL Fatigue Short Form: Some concerns (Cochrane RoB 2); Patient Global Assessment: Some concerns (Cochrane RoB 2); Physician Global Assessment: Some concerns (Cochrane RoB 2); Triple Timed Up and Go test: Some concerns (Cochrane RoB 2); Wrist and hip accelerometry: Some concerns (Cochrane RoB 2); Adverse events: Some concerns (Cochrane RoB 2)

Full study record (PLS-00116)
EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention.Randomized controlled trial · Not reported participants · first reported 2015 · automated, not human-reviewed

Population: Adults with first-time anterior ST-elevation myocardial infarction due to a proximal or mid left anterior descending artery occlusion who were undergoing primary percutaneous coronary intervention.

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Infarct size by CK-MB area under the curve over 72 h: Some concerns (Cochrane RoB 2); Pre-specified MRI, angiographic and electrocardiographic outcomes: High risk of bias (Cochrane RoB 2); Clinical outcomes: High risk of bias (Cochrane RoB 2); Safety and tolerability: High risk of bias (Cochrane RoB 2)

Full study record (PLS-00117)
Initial Psychometric Evaluation of the Barth Syndrome Symptom Assessment (BTHS-SA) for Adolescents and Adults in a Phase 2 Clinical Study.Randomized controlled trial · 12 participants · first reported 2025 · automated, not human-reviewed

Population: Adolescent and adult white males with genetically confirmed Barth syndrome (TAZ mutations). Mean age 19.5 years (SD 7.7). Overall symptoms were rated mild to very severe.

Assessed from the abstract only: essential methods may be missing.

Full study record (PLS-00118)
Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.Randomized controlled trial · 36 participants · first reported 2015 · automated, not human-reviewed

Population: Patients with heart failure with reduced ejection fraction (ejection fraction at or below 35%)

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Left ventricular end-diastolic volume: High risk of bias (Cochrane RoB 2); Left ventricular end-systolic volume: High risk of bias (Cochrane RoB 2); Serious adverse events: Some concerns (Cochrane RoB 2)

Full study record (PLS-00120)
In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial.Randomized controlled trial · 39 participants · first reported 2021 · automated, not human-reviewed

Population: Healthy older adults aged 60 to 85 years (46% female), enrolled because they had poorly functioning skeletal muscle mitochondria. The first dorsal interosseous muscle was studied.

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Mitochondrial energetic capacity (ATPmax) during exercise: Some concerns (Cochrane RoB 2); Resting mitochondrial coupling (P/O, ATP supply per O2 uptake): Some concerns (Cochrane RoB 2); Volitional fatigue resistance: Some concerns (Cochrane RoB 2)

Full study record (PLS-00121)
Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis.Randomized controlled trial · 16 participants · first reported 2012 · automated, not human-reviewed

Population: Patients with severe atherosclerotic renal artery stenosis scheduled for percutaneous transluminal renal angioplasty (PTRA) and stenting; age and baseline glomerular filtration rate did not differ between groups.

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Stenotic kidney fractional hypoxia: High risk of bias (Cochrane RoB 2); Stenotic kidney renal blood flow: High risk of bias (Cochrane RoB 2); Estimated glomerular filtration rate: High risk of bias (Cochrane RoB 2); Systolic blood pressure: High risk of bias (Cochrane RoB 2)

Full study record (PLS-00122)
The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction.Randomized controlled trial · 35 participants · first reported 2017 · automated, not human-reviewed

Population: Patients with first-time acute anterior ST-segment elevation myocardial infarction after percutaneous coronary intervention (n=19, a subset of the EMBRACE trial), plus a reference group of healthy blood donors (n=16).

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Serum HtrA2 level: High risk of bias (Cochrane RoB 2)

Full study record (PLS-00123)
Urinary mitochondrial DNA copy number identifies renal mitochondrial injury in renovascular hypertensive patients undergoing renal revascularization: A Pilot Study.Other design · 19 participants · first reported 2019 · automated, not human-reviewed

Population: Patients with renovascular hypertension undergoing percutaneous transluminal renal angioplasty (PTRA), plus healthy volunteers as reference controls.

Assessed from the abstract only: essential methods may be missing.

Full study record (PLS-00124)
Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial).Randomized controlled trial · 300 participants · first reported 2012 · automated, not human-reviewed

Population: Patients with a first anterior ST-segment elevation myocardial infarction, an occluded left anterior descending artery and an available LV mass measurement in the EMBRACE STEMI trial (n = 100 in this post hoc analysis).

Assessed from the abstract only: essential methods may be missing.

Risk of bias: CK-MB area under the curve (biomarker infarct size): High risk of bias (Cochrane RoB 2); Troponin I area under the curve (biomarker infarct size): High risk of bias (Cochrane RoB 2); Myocardial salvage index: High risk of bias (Cochrane RoB 2)

Full study record (PLS-00125)
Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy AdultsOther design · 40 participants · first reported 2010 · automated, not human-reviewed

Population: Healthy adults

Full study record (PLS-00213)
Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without BendaviaOther design · 12 participants · first reported 2012 · automated, not human-reviewed

Population: Healthy volunteers

Full study record (PLS-00216)
The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette SmokingOther design · 6 participants · first reported 2012 · automated, not human-reviewed

Population: Healthy volunteers exposed to cigarette smoking. Smoking status and other eligibility details are not stated in the record.

Full study record (PLS-00217)
A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131)Other design · 30 participants · first reported 2012 · automated, not human-reviewed

Population: Healthy volunteers

Full study record (PLS-00218)
Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 DaysOther design · 30 participants · first reported 2013 · automated, not human-reviewed

Population: Healthy volunteers

Full study record (PLS-00219)
A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in ElderlyOther design · 41 participants · first reported 2014 · automated, not human-reviewed

Population: Elderly people with skeletal muscle mitochondrial dysfunction

Full study record (PLS-00220)
A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular DegenerationOther design · 20 participants · first reported 2014 · automated, not human-reviewed

Population: Subjects with diabetic macular edema or non-exudative intermediate age-related macular degeneration

Full study record (PLS-00221)
Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial MyopathyOther design · 36 participants · first reported 2015 · automated, not human-reviewed

Population: People with mitochondrial myopathy. Age and other eligibility details are not stated in the record.

Full study record (PLS-00222)
A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal FunctionOther design · 23 participants · first reported 2015 · automated, not human-reviewed

Population: Subjects with impaired renal function (registered condition: normal and impaired renal function)

Full study record (PLS-00224)
A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)Other design · 22 participants · first reported 2016 · automated, not human-reviewed

Population: People with Fuchs' corneal endothelial dystrophy (FCED).

Full study record (PLS-00228)
A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic NeuropathyOther design · 12 participants · first reported 2016 · automated, not human-reviewed

Population: People with Leber's hereditary optic neuropathy

Full study record (PLS-00229)
Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection FractionOther design · 71 participants · first reported 2016 · automated, not human-reviewed

Population: Adults with stable heart failure with reduced ejection fraction (per study title)

Full study record (PLS-00230)
Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER StudyOther design · 30 participants · first reported 2016 · automated, not human-reviewed

Population: Subjects with primary mitochondrial disease drawn from the earlier MMPOWER study. Age range and other eligibility details are not stated in the record.

Full study record (PLS-00231)
A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection FractionOther design · 46 participants · first reported 2016 · automated, not human-reviewed

Population: Adults with stable heart failure with preserved ejection fraction (registered condition: chronic heart failure).

Full study record (PLS-00232)
An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular DegenerationSingle-arm trial · 40 participants · first reported 2016 · automated, not human-reviewed

Population: Subjects with intermediate age-related macular degeneration

Full study record (PLS-00233)
A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart FailureOther design · 308 participants · first reported 2016 · automated, not human-reviewed

Population: Patients hospitalized with congestion due to heart failure

Full study record (PLS-00234)
Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)Single-arm trial · 28 participants · first reported 2016 · automated, not human-reviewed

Population: Subjects with genetically confirmed primary mitochondrial myopathy (PMM) entering an open-label extension

Full study record (PLS-00236)
An Intermediate Size Expanded Access Protocol of ElamipretideOther design · Not reported participants · first reported 2020 · automated, not human-reviewed

Population: People with mitochondrial diseases, including Barth syndrome, receiving elamipretide under an intermediate-size expanded access protocol.

Full study record (PLS-00240)
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)Other design · 102 participants · first reported 2021 · automated, not human-reviewed

Population: Subjects with primary mitochondrial disease caused by nuclear DNA mutations (nPMD). Age and other eligibility details are not stated in the record.

Full study record (PLS-00241)
FRDA Investigator Initiated Study (IIS) With ElamipretideOther design · 20 participants · first reported 2021 · automated, not human-reviewed

Population: People with Friedreich ataxia

Full study record (PLS-00242)
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)Other design · 313 participants · first reported 2024 · automated, not human-reviewed

Population: Subjects with dry age-related macular degeneration (dry AMD)

Full study record (PLS-00244)
Study of Healthy Aging and Physical Function With ElamipretideOther design · Not reported participants · first reported 2025 · automated, not human-reviewed

Population: Healthy aging adults (registered condition: Aging, Healthy); eligibility details not provided in the record

Full study record (PLS-00245)
Clinical Trial in Patients With Barth Syndrome- 4TAZPowerOther design · Not reported participants · first reported 2026 · automated, not human-reviewed

Population: Patients with Barth syndrome. Eligibility criteria and age range are not stated in the record.

Full study record (PLS-00250)
Records reviewed and excluded (3)
  • The Mitochondrial Antioxidant SS-31 Modulates Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy in Type 2 Diabetes.: not human
  • The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes.: not human
  • A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failure: other

Why the counts differ

Publications, studies and registrations are different units.

These numbers count different things. The research snapshot 2026.1.1 counts 30 human clinical publications: PubMed records, classified by publication type. Here, each reviewed study is counted once (51 in all), however many reports describe it (30 PubMed records, 30 registrations, 0 other reports such as meeting abstracts outside PubMed).

Which source records describe which study
StudySource recordRole
PLS-00036 (excluded)PMID 31466264The Mitochondrial Antioxidant SS-31 Modulates Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy in Type 2 Diabetes.primary
PLS-00097PMID 42415111Elamipretide in pediatric Barth syndrome: from heart failure to school return.primary
PLS-00098PMID 39619320Expanded-Access Use of Elamipretide Improves Quality of Life in Patients With Rare Mitochondrial Disorders Characterized by Ophthalmic Symptoms: A Case Series.primary
PLS-00099PMID 39917770Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report.primary
PLS-00100PMID 39574155Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.primary
PLS-00100NCT03323749 · results postedA Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extensionregistry entry
PLS-00101PMID 40645388Cardiac pathology in a patient with a novel pathogenic variant c.703del (p.Ile235SerfsTer4) of the TAFAZZIN gene.primary
PLS-00102PMID 40816230Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report.primary
PLS-00103PMID 38919884Expanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration.primary
PLS-00104PMID 39605874ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation.primary
PLS-00104NCT03891875 · results postedReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GAregistry entry
PLS-00105PMID 37923251Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.primary
PLS-00106PMID 38602181Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.primary
PLS-00106NCT03098797 · results postedA Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndromeregistry entry
PLS-00107PMID 37268435Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.primary
PLS-00108PMID 36636586Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases.primary
PLS-00109PMID 37041653Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.primary
PLS-00110PMID 36056411Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.primary
PLS-00111PMID 29500292Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.primary
PLS-00112PMID 33077895A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.primary
PLS-00113PMID 36246187Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.primary
PLS-00114PMID 36246181Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study.primary
PLS-00115PMID 32068002Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial.primary
PLS-00116PMID 32096613A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.primary
PLS-00117PMID 26586786EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention.primary
PLS-00118PMID 40281531Initial Psychometric Evaluation of the Barth Syndrome Symptom Assessment (BTHS-SA) for Adolescents and Adults in a Phase 2 Clinical Study.primary
PLS-00119 (excluded)PMID 30367115The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes.primary
PLS-00120PMID 29217757Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.primary
PLS-00120NCT02388464 · no results postedA Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failureregistry entry
PLS-00121PMID 34264994In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial.primary
PLS-00122PMID 28916603Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis.primary
PLS-00122NCT01755858 · results postedEffects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Arteryregistry entry
PLS-00123PMID 28534645The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction.primary
PLS-00124PMID 30803138Urinary mitochondrial DNA copy number identifies renal mitochondrial injury in renovascular hypertensive patients undergoing renal revascularization: A Pilot Study.primary
PLS-00125PMID 27392509Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial).primary
PLS-00125NCT01572909 · results postedEvaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Eventsregistry entry
PLS-00213NCT01115920 · no results postedStudy to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adultsregistry entry
PLS-00216NCT01513200 · no results postedStudy to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendaviaregistry entry
PLS-00217NCT01518985 · no results postedThe Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smokingregistry entry
PLS-00218NCT01754818 · no results postedA Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131)registry entry
PLS-00219NCT01786915 · no results postedSafety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Daysregistry entry
PLS-00220NCT02245620 · results postedA Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderlyregistry entry
PLS-00221NCT02314299 · no results postedA Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degenerationregistry entry
PLS-00222NCT02367014 · results postedSafety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathyregistry entry
PLS-00223 (excluded)NCT02388529 · no results postedA Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failureregistry entry
PLS-00224NCT02436447 · no results postedA Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Functionregistry entry
PLS-00228NCT02653391 · results postedA Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)registry entry
PLS-00229NCT02693119 · results postedA Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathyregistry entry
PLS-00230NCT02788747 · results postedEffect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fractionregistry entry
PLS-00231NCT02805790 · results postedSafety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Studyregistry entry
PLS-00232NCT02814097 · no results postedA Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fractionregistry entry
PLS-00233NCT02848313 · results postedAn Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degenerationregistry entry
PLS-00234NCT02914665 · no results postedA Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failureregistry entry
PLS-00236NCT02976038 · results postedOpen-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)registry entry
PLS-00240NCT04689360 · no results postedAn Intermediate Size Expanded Access Protocol of Elamipretideregistry entry
PLS-00241NCT05162768 · no results postedStudy to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)registry entry
PLS-00242NCT05168774 · results postedFRDA Investigator Initiated Study (IIS) With Elamipretideregistry entry
PLS-00244NCT06373731 · no results postedReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)registry entry
PLS-00245NCT07275424 · no results postedStudy of Healthy Aging and Physical Function With Elamipretideregistry entry
PLS-00250NCT07531251 · no results postedClinical Trial in Patients With Barth Syndrome- 4TAZPowerregistry entry

Evidence gaps

  • Research activity gap: No gap identified

    Little indexed research of any kind.

  • Human research gap: No gap identified

    Laboratory or animal research exists, but little human research.

  • Evidence quality gap: Gap identified

    Human research exists, but no assessed outcome reaches moderate or high certainty.

  • Clinical relevance gap: No gap identified

    Studies exist but none directly address a claim being evaluated.

  • Safety evidence gap: Gap identified

    Safety is not established with moderate or high certainty for the populations, routes or durations studied.

Timeline

Registrations, publications, posted results and every change to the assessments.

  1. 2010-05-04

    Registered: NCT01115920

  2. 2012-01-20

    Registered: NCT01513200

  3. 2012-01-26

    Registered: NCT01518985

  4. 2012-04-06

    Registered: NCT01572909

  5. 2012-12-21

    Registered: NCT01754818

  6. 2012-12-24

    Registered: NCT01755858

  7. 2013-02-08

    Registered: NCT01786915

  8. 2014-09-19

    Registered: NCT02245620

  9. 2014-12-11

    Registered: NCT02314299

  10. 2015-02-20

    Registered: NCT02367014

  11. 2015-03-17

    Registered: NCT02388464

  12. 2015-03-17

    Registered: NCT02388529

  13. 2015-05-06

    Registered: NCT02436447

  14. 2015-11-19

    Published: EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention.

  15. 2016-01-12

    Registered: NCT02653391

  16. 2016-02-26

    Registered: NCT02693119

  17. 2016-06-02

    Registered: NCT02788747

  18. 2016-06-15

    Published: Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial).

  19. 2016-06-20

    Registered: NCT02805790

  20. 2016-06-27

    Registered: NCT02814097

  21. 2016-07-28

    Registered: NCT02848313

  22. 2016-09-26

    Registered: NCT02914665

  23. 2016-11-29

    Registered: NCT02976038

  24. 2017-04-04

    Registered: NCT03098797

  25. 2017-05-23

    Published: The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction.

  26. 2017-09-01

    Published: Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis.

  27. 2017-10-27

    Registered: NCT03323749

  28. 2017-12-01

    Published: Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.

  29. 2018-03-02

    Published: Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.

  30. 2018-10-26

    Published: The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes.

  31. 2019-03-13

    Published: Urinary mitochondrial DNA copy number identifies renal mitochondrial injury in renovascular hypertensive patients undergoing renal revascularization: A Pilot Study.

  32. 2019-03-27

    Registered: NCT03891875

  33. 2019-08-28

    Published: The Mitochondrial Antioxidant SS-31 Modulates Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy in Type 2 Diabetes.

  34. 2019-12-27

    Results posted: NCT02367014

  35. 2020-02-14

    Published: Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial.

  36. 2020-02-25

    Published: A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.

  37. 2020-04-22

    Results posted: NCT02788747

  38. 2020-06-11

    Results posted: NCT01572909

  39. 2020-06-23

    Results posted: NCT02245620

  40. 2020-07-07

    Results posted: NCT02805790

  41. 2020-08-11

    Results posted: NCT01755858

  42. 2020-09-21

    Results posted: NCT02848313

  43. 2020-10-20

    Published: A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.

  44. 2020-12-30

    Registered: NCT04689360

  45. 2021-04-02

    Results posted: NCT03323749

  46. 2021-07-15

    Published: In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial.

  47. 2021-09-17

    Results posted: NCT02653391

  48. 2021-10-12

    Results posted: NCT02693119

  49. 2021-11-27

    Published: Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study.

  50. 2021-12-17

    Registered: NCT05162768

  51. 2021-12-17

    Results posted: NCT02976038

  52. 2021-12-22

    Published: Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.

  53. 2021-12-23

    Registered: NCT05168774

  54. 2022-09-02

    Published: Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.

  55. 2022-09-21

    Published: Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases.

  56. 2023-04-11

    Published: Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.

  57. 2023-06-02

    Published: Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.

  58. 2023-10-17

    Results posted: NCT03891875

  59. 2023-11-03

    Published: Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.

  60. 2024-04-08

    Published: Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.

  61. 2024-04-16

    Results posted: NCT03098797

  62. 2024-04-18

    Registered: NCT06373731

  63. 2024-06-24

    Published: Expanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration.

  64. 2024-10-09

    Published: ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation.

  65. 2024-11-21

    Published: Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.

  66. 2024-11-29

    Published: Expanded-Access Use of Elamipretide Improves Quality of Life in Patients With Rare Mitochondrial Disorders Characterized by Ophthalmic Symptoms: A Case Series.

  67. 2025-01-22

    Published: Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report.

  68. 2025-04-25

    Published: Initial Psychometric Evaluation of the Barth Syndrome Symptom Assessment (BTHS-SA) for Adolescents and Adults in a Phase 2 Clinical Study.

  69. 2025-07-10

    Published: Cardiac pathology in a patient with a novel pathogenic variant c.703del (p.Ile235SerfsTer4) of the TAFAZZIN gene.

  70. 2025-08-11

    Published: Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report.

  71. 2025-12-10

    Registered: NCT07275424

  72. 2025-12-12

    Results posted: NCT05168774

  73. 2026-04-15

    Registered: NCT07531251

  74. 2026-07-07

    Published: Elamipretide in pediatric Barth syndrome: from heart failure to school return.

  75. 2026-11-07

    Risk-of-bias assessment published (version 1)

  76. 2026-11-07

    Risk-of-bias assessment published (version 1)

  77. 2026-11-07

    Risk-of-bias assessment published (version 1)

  78. 2026-11-07

    Risk-of-bias assessment published (version 1)

  79. 2026-11-07

    Risk-of-bias assessment published (version 1)

  80. 2026-11-07

    Risk-of-bias assessment published (version 1)

  81. 2026-11-07

    Risk-of-bias assessment published (version 1)

  82. 2026-11-07

    Risk-of-bias assessment published (version 1)

  83. 2026-11-07

    Risk-of-bias assessment published (version 1)

  84. 2026-11-07

    Risk-of-bias assessment published (version 1)

  85. 2026-11-07

    Risk-of-bias assessment published (version 1)

  86. 2026-11-07

    Risk-of-bias assessment published (version 1)

  87. 2026-11-07

    Risk-of-bias assessment published (version 1)

  88. 2026-11-07

    Risk-of-bias assessment published (version 1)

  89. 2026-11-07

    Risk-of-bias assessment published (version 1)

  90. 2026-11-07

    Risk-of-bias assessment published (version 1)

  91. 2026-11-07

    Risk-of-bias assessment published (version 1)

  92. 2026-11-07

    Risk-of-bias assessment published (version 1)

  93. 2026-11-07

    Risk-of-bias assessment published (version 1)

  94. 2026-11-07

    Risk-of-bias assessment published (version 1)

  95. 2026-11-07

    Risk-of-bias assessment published (version 1)

  96. 2026-11-07

    Risk-of-bias assessment published (version 1)

  97. 2026-11-07

    Risk-of-bias assessment published (version 1)

  98. 2026-11-07

    Risk-of-bias assessment published (version 1)

  99. 2026-11-07

    Risk-of-bias assessment published (version 1)

  100. 2026-11-07

    Risk-of-bias assessment published (version 1)

  101. 2026-11-07

    Risk-of-bias assessment published (version 1)

  102. 2026-11-07

    Risk-of-bias assessment published (version 1)

  103. 2026-11-07

    Risk-of-bias assessment published (version 1)

  104. 2026-11-07

    Risk-of-bias assessment published (version 1)

  105. 2026-11-07

    Risk-of-bias assessment published (version 1)

  106. 2026-11-07

    Risk-of-bias assessment published (version 1)

  107. 2026-11-07

    Risk-of-bias assessment published (version 1)

  108. 2026-11-07

    Risk-of-bias assessment published (version 1)

  109. 2026-11-07

    Risk-of-bias assessment published (version 1)

  110. 2026-11-07

    Risk-of-bias assessment published (version 1)

  111. 2026-11-07

    Risk-of-bias assessment published (version 1)

  112. 2026-11-07

    Risk-of-bias assessment published (version 1)

  113. 2026-11-07

    Risk-of-bias assessment published (version 1)

  114. 2026-11-07

    Risk-of-bias assessment published (version 1)

  115. 2026-11-07

    Risk-of-bias assessment published (version 1)

  116. 2026-11-07

    Risk-of-bias assessment published (version 1)

  117. 2026-11-07

    Risk-of-bias assessment published (version 1)

  118. 2026-11-07

    Risk-of-bias assessment published (version 1)

  119. 2026-11-07

    Risk-of-bias assessment published (version 1)

  120. 2026-11-07

    Risk-of-bias assessment published (version 1)

  121. 2026-11-07

    Risk-of-bias assessment published (version 1)

  122. 2026-11-07

    Risk-of-bias assessment published (version 1)

  123. 2026-11-07

    Risk-of-bias assessment published (version 1)

  124. 2026-11-07

    Risk-of-bias assessment published (version 1)

  125. 2026-11-07

    Risk-of-bias assessment published (version 1)

  126. 2026-11-07

    Risk-of-bias assessment published (version 1)

  127. 2026-11-07

    Risk-of-bias assessment published (version 1)

  128. 2026-11-07

    Risk-of-bias assessment published (version 1)

  129. 2026-11-07

    Risk-of-bias assessment published (version 1)

  130. 2026-11-07

    Risk-of-bias assessment published (version 1)

  131. 2026-11-07

    Risk-of-bias assessment published (version 1)

  132. 2026-11-07

    Risk-of-bias assessment published (version 1)

  133. 2026-11-07

    Risk-of-bias assessment published (version 1)

  134. 2026-11-07

    Risk-of-bias assessment published (version 1)

  135. 2026-11-07

    Risk-of-bias assessment published (version 1)

  136. 2026-11-07

    Risk-of-bias assessment published (version 1)

  137. 2026-11-07

    Risk-of-bias assessment published (version 1)

  138. 2026-11-07

    Risk-of-bias assessment published (version 1)

  139. 2026-11-07

    Risk-of-bias assessment published (version 1)

  140. 2026-11-07

    Risk-of-bias assessment published (version 1)

  141. 2026-11-07

    Risk-of-bias assessment published (version 1)

  142. 2026-11-07

    Risk-of-bias assessment published (version 1)

  143. 2026-11-07

    Risk-of-bias assessment published (version 1)

  144. 2026-11-07

    Risk-of-bias assessment published (version 1)

  145. 2026-11-07

    Risk-of-bias assessment published (version 1)

  146. 2026-11-07

    Risk-of-bias assessment published (version 1)

  147. 2026-11-07

    Risk-of-bias assessment published (version 1)

  148. 2026-11-07

    Risk-of-bias assessment published (version 1)

  149. 2026-11-07

    Risk-of-bias assessment published (version 1)

  150. 2026-11-07

    Risk-of-bias assessment published (version 1)

  151. 2026-11-07

    Risk-of-bias assessment published (version 1)

  152. 2026-11-07

    Risk-of-bias assessment published (version 1)

  153. 2026-11-07

    Risk-of-bias assessment published (version 1)

  154. 2026-11-07

    Risk-of-bias assessment published (version 1)

  155. 2026-11-07

    Risk-of-bias assessment published (version 1)

  156. 2026-11-07

    Risk-of-bias assessment published (version 1)

  157. 2026-11-07

    Risk-of-bias assessment published (version 1)

  158. 2026-11-07

    Risk-of-bias assessment published (version 1)

  159. 2026-11-07

    Study record published (version 1)

  160. 2026-11-07

    Study record published (version 1)

  161. 2026-11-07

    Study record published (version 1)

  162. 2026-11-07

    Study record published (version 1)

  163. 2026-11-07

    Study record published (version 1)

  164. 2026-11-07

    Study record published (version 1)

  165. 2026-11-07

    Study record published (version 1)

  166. 2026-11-07

    Study record published (version 1)

  167. 2026-11-07

    Study record published (version 1)

  168. 2026-11-07

    Study record published (version 1)

  169. 2026-11-07

    Study record published (version 1)

  170. 2026-11-07

    Study record published (version 1)

  171. 2026-11-07

    Study record published (version 1)

  172. 2026-11-07

    Study record published (version 1)

  173. 2026-11-07

    Study record published (version 1)

  174. 2026-11-07

    Study record published (version 1)

  175. 2026-11-07

    Study record published (version 1)

  176. 2026-11-07

    Study record published (version 1)

  177. 2026-11-07

    Study record published (version 1)

  178. 2026-11-07

    Study record published (version 1)

  179. 2026-11-07

    Study record published (version 1)

  180. 2026-11-07

    Study record published (version 1)

  181. 2026-11-07

    Study record published (version 1)

  182. 2026-11-07

    Study record published (version 1)

  183. 2026-11-08

    Claim assessment published (version 1)

  184. 2026-11-08

    Claim assessment published (version 1)

  185. 2026-11-08

    Claim assessment published (version 1)

  186. 2026-11-08

    Certainty assessment published (version 1)

  187. 2026-11-08

    Certainty assessment published (version 1)

  188. 2026-11-08

    Certainty assessment published (version 1)

  189. 2026-11-08

    Risk-of-bias assessment published (version 1)

  190. 2026-11-08

    Risk-of-bias assessment published (version 1)

  191. 2026-11-08

    Risk-of-bias assessment published (version 1)

  192. 2026-11-08

    Risk-of-bias assessment published (version 1)

  193. 2026-11-08

    Risk-of-bias assessment published (version 1)

  194. 2026-11-08

    Risk-of-bias assessment published (version 1)

  195. 2026-11-08

    Risk-of-bias assessment published (version 1)

  196. 2026-11-08

    Risk-of-bias assessment published (version 1)

  197. 2026-11-08

    Risk-of-bias assessment published (version 1)

  198. 2026-11-08

    Risk-of-bias assessment published (version 1)

  199. 2026-11-08

    Risk-of-bias assessment published (version 1)

  200. 2026-11-08

    Risk-of-bias assessment published (version 1)

  201. 2026-11-08

    Risk-of-bias assessment published (version 1)

  202. 2026-11-08

    Risk-of-bias assessment published (version 1)

  203. 2026-11-08

    Risk-of-bias assessment published (version 1)

  204. 2026-11-08

    Risk-of-bias assessment published (version 1)

  205. 2026-11-08

    Study record published (version 1)

  206. 2026-11-08

    Study record published (version 1)

  207. 2026-11-08

    Study record published (version 1)

  208. 2026-11-08

    Study record published (version 1)

  209. 2026-11-08

    Study record published (version 1)

  210. 2026-11-08

    Study record published (version 1)

  211. 2026-11-08

    Study record published (version 1)

  212. 2026-11-08

    Study record published (version 1)

  213. 2026-11-08

    Study record published (version 1)

  214. 2026-11-08

    Study record published (version 1)

  215. 2026-11-08

    Study record published (version 1)

  216. 2026-11-08

    Study record published (version 1)

  217. 2026-11-08

    Study record published (version 1)

  218. 2026-11-08

    Study record published (version 1)

  219. 2026-11-08

    Study record published (version 1)

  220. 2026-11-08

    Study record published (version 1)

  221. 2026-11-08

    Study record published (version 1)

  222. 2026-11-08

    Study record published (version 1)

  223. 2026-11-08

    Study record published (version 1)

  224. 2026-11-08

    Study record published (version 1)

  225. 2026-11-08

    Study record published (version 1)

  226. 2026-11-08

    Study record published (version 1)

  227. 2026-11-08

    Study record published (version 1)

  228. 2026-11-08

    Study record published (version 1)

  229. 2026-11-08

    Study record published (version 1)

  230. 2026-11-08

    Study record published (version 1)

  231. 2026-11-08

    Study record published (version 1)

  232. 2026-11-08

    Study record published (version 1)

  233. 2026-11-08

    Study record published (version 1)

  234. 2026-11-08

    Study record published (version 1)

Sources and method

Every assessment links its sources and keeps its full version history. Methodology · All assessments (CSV) · All study records (CSV)

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).